A Study of CS1001 in Subjects With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety,
tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced
solid tumors.